Professor Andrew Ustianowski, NIHR Clinical Lead for the COVID-19 Vaccination Programme and Joint National Infection Specialty Lead, added: “We know that the Oxford-AstraZeneca two-dose schedule is highly effective and has helped to save many lives.
“The fact we now know it works well, in terms of immune responses, when combined with the Pfizer vaccine provides researchers with the valuable knowledge that these vaccines could be used flexibly for those yet to be vaccinated in the UK and globally.
“It would have been impossible to discover these results without the willingness and efforts of research participants across the country. Yet again they have worked alongside researchers to help find an end to the spread of COVID-19.”
In May, researchers reported preliminary Com-COV data revealing more frequent mild to moderate reactions in mixed schedules compared to standard schedules, however, these were short-lived in duration.
